| Literature DB >> 31991768 |
Lucie Podešvová1, Tereza Leštinová2, Eva Horáková3, Julius Lukeš3,4, Petr Volf2, Vyacheslav Yurchenko1,5.
Abstract
Leishmania are obligate intracellular parasites known to have developed successful ways of efficient immunity evasion. Because of this, leishmaniasis, a disease caused by these flagellated protists, is ranked as one of the most serious tropical infections worldwide. Neither prophylactic medication, nor vaccination has been developed thus far, even though the infection has usually led to strong and long-lasting immunity. In this paper, we describe a "suicidal" system established in Leishmania mexicana, a human pathogen causing cutaneous leishmaniasis. This system is based on the expression and (de)stabilization of a basic phospholipase A2 toxin from the Bothrops pauloensis snake venom, which leads to the inducible cell death of the parasites in vitro. Furthermore, the suicidal strain was highly attenuated during macrophage infection, regardless of the toxin stabilization. Such a deliberately weakened parasite could be used to vaccinate the host, as its viability is regulated by the toxin stabilization, causing a profoundly reduced pathogenesis.Entities:
Keywords: BnSP-7; Leishmania mexicana; apoptosis; ecDHFR; suicidal system
Year: 2020 PMID: 31991768 PMCID: PMC7168676 DOI: 10.3390/pathogens9020079
Source DB: PubMed Journal: Pathogens ISSN: 2076-0817
Figure 1Growth kinetics of Leishmania mexicana expressing the BnSP-7 toxin. (A) Growth curves of the wild type and BnSP-7-ecDHFR-HA-expressing L. mexicana after induction with 20 μM Trimethoprim (TMP)/Trimethoprim-lactate (TMP-lac); (B) growth curves of BnSP-7-ecDHFR-HA-expressing L. mexicana, cultivated for 8 days with continuous replenishment of TMP or DMSO; (C) TMP facilitates decrease in a number of BnSP-7-ecDHFR-HA-expressing L. mexicana. All data are derived from three independent biological replicates. The error bars indicate standard deviations.
Figure 2Cell death of L. mexicana expressing the BnSP-7 toxin. (A) Flow cytometry analysis of the L. mexicana cells treated with TMP or TMP-lac for 5 days. Hygromycin B treated wild type L. mexicana cells were used as an apoptotic/necrotic control; (B) apoptosis and necrosis were quantified after FITC-Annexin V and PI labeling; bar graphs represent mean ± SD in three independent experiments; asterisks indicate p values; * ≤0.05, ** ≤0.01, *** ≤0.001; (C) fluorescence microscopy of the Annexin V-FITC, PI, and DAPI (left panels), Annexin V-FITC and DAPI (middle panels) stained, and light microscopy controls (right panels) of the L. mexicana BnSP-7-ecDHFR-HA cells prior and after induction by the stabilization ligand for 48 hours. Scale bars are 10 μm.
Figure 3Protein levels of BnSP-7-ecDHFR-HA and BnSP-7-ecDHFR-HA3 after induction by TMP/TMP-lac in L. mexicana. (A) Western blot of the untreated promastigote lysates and those treated with 20 μM TMP for 48 hours; (B) Western blot of the untreated amastigote lysates and those treated with 20 μM TMP for 48 hours. Tubulin served as a loading control. Arrows indicate the band of the expected size (32 kDa and 34 kDa for HA- or HA3-tagged proteins, respectively).
Figure 4Relative rates of L. mexicana infectivity. (A) Macrophage infection by the wild type and the BnSP-7-ecDHFR-HA-expressing cells; (B) macrophage infection by the wild type and the BnSP-7-ecDHFR-HA-expressing cells treated with 20 μM TMP-lac for 48 hours. Data are presented as percentage of the wild type parasites (A) or saline-treated controls (B), taken at 100%. The error bars indicate standard deviation derived from the two independent biological experiments (with 3 technical replicated each).
List of toxins/antimicrobial peptides fused with mut 2 ecDHFR-HA [22] and their toxic properties.
| AMP/Toxin | Source | Mass (kDa) | Activity |
|---|---|---|---|
| Alpha-toxin |
| 35.9 | plasma membrane permeabilization |
| Attacin-A |
| 21.7 | plasma membrane permeabilization |
| BnSP-7 |
| 13.7 | plasma membrane permeabilization |
| Cathelicidin-5 (BMAP-28) |
| 17.6 | plasma membrane permeabilization |
| Cecropin-A |
| 6.9 | plasma membrane permeabilization |
| Exotoxin-A |
| 69 | elongation factor-2 inhibition |